Pregnancy and Bromocriptine (3)	
	
There is little doubt that patients with pituitary tumours run a small, but significant, risk of expansion of the tumour during pregnancy. It is very difficult, however, to assess the absolute risk. With microadenomas, the incidence seems to be less than one per cent and probably less than 0.5 per cent. In patients with macroadenomas, the incidence is probably higher, perhaps between five and twenty per cent. This risk is unrelated to bromocriptine therapy prior to pregnancy but may occur when fertility is induced with other drugs, including exogenous gonadotrophins and clomiphene, and even when no drug therapy has been employed in patients with pre-existing pituitary adenomas.
In practice, the problem of pregnancy is not great since the vast majority of women who present with hyperprolactinaemia only have microadenomas.